Does Rallies show 13F holders for KALV?

Yes. Rallies tracks hedge fund and 13F ownership data for KALV, including fund names, share counts, latest tracked quarter, and position changes when available.

Is KALV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KALV. It does not provide personalized investment advice.

KALV (KalVista Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

KalVista Pharmaceuticals, Inc. Common Stock (KALV) is a publicly traded Healthcare sector company. As of May 20, 2026, KALV trades at $26.77 with a market cap of $1.42B and a P/E ratio of -7.25. KALV moved +0.00% today. Year to date, KALV is +73.16%; over the trailing twelve months it is +121.79%. Its 52-week range spans $7.30 to $26.85. Analyst consensus is neutral with an average price target of $29.17. Rallies surfaces KALV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns KALV stock?

Hedge funds tracked by Rallies that own KALV include Orbimed Advisors, Centerbook Partners, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for KalVista Pharmaceuticals, Inc. Common Stock.

KALV Key Metrics

Key financial metrics for KALV
Metric	Value
Price	$26.77
Market Cap	$1.42B
P/E Ratio	-7.25
EPS	$-3.69
Dividend Yield	0.00%
52-Week High	$26.85
52-Week Low	$7.30
Volume	7.34M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-183.44M
Gross Margin	0.00%

Top Hedge Funds Holding KALV

Orbimed Advisors holds 94.40K shares of KALV, changed -75.31% as of Mar 31, 2026.
Centerbook Partners holds 53.26K shares of KALV, changed +0.00% as of Mar 31, 2026.
Panagora Asset holds 50.79K shares of KALV, changed -53.57% as of Mar 31, 2026.

Latest KALV News

Halper Sadeh Challenges KalVista’s $27 Cash Deal, Seeks Higher Consideration — May 19, 2026
Chiesi to Buy KalVista for $1.9B at 36% Premium — Apr 30, 2026
Chiesi Agrees $1.9B KalVista Deal at $27 Per Share as Citigroup Downgrades — Apr 29, 2026

Recent KALV Insider Trades

Palleiko Benjamin L sold 3.32K (~$88.73K) on May 12, 2026.
Audhya Paul K. sold 2.69K (~$54.30K) on Apr 17, 2026.
Sweeny Nicole sold 1.86K (~$37.64K) on Apr 17, 2026.

KALV Analyst Consensus

8 analysts cover KALV: 0 strong buy, 2 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $29.17.

Common questions about KALV

Who owns KALV stock?: Hedge funds tracked by Rallies that own KALV include Orbimed Advisors, Centerbook Partners, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for KalVista Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for KALV?: Yes. Rallies tracks hedge fund and 13F ownership data for KALV, including fund names, share counts, latest tracked quarter, and position changes when available.
Is KALV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KALV. It does not provide personalized investment advice.